Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox in Transfusion-dependent Iron Overload
NCT00171821Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Serum Ferritin Level at 52 weeks. Started Apr 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT00171821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171821.